Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” fourth quarter 2024, investor letter. A copy of the letter can be downloaded here. The fourth quarter concluded the portfolio’s successful year in comparison to its benchmark index. The strategy returned -0.17%, net of fees, in the quarter, compared to -0.99% return for the MSCI AC World Net Index. From a sector standpoint, the main drivers of the portfolio’s outperformance during the quarter were Industrials and Materials. In addition, please check the fund’s top five holdings to know its best picks in 2024.
In its fourth quarter 2024 investor letter, Hardman Johnston Global Equity Strategy emphasized stocks such as IQVIA Holdings Inc. (NYSE:IQV). IQVIA Holdings Inc. (NYSE:IQV) is an analytical technology services and clinical research-providing company to the life sciences industry. The one-month return IQVIA Holdings Inc. (NYSE:IQV) was -3.55%, and its shares lost 27.00% of their value over the last 52 weeks. On March 20, 2025, IQVIA Holdings Inc. (NYSE:IQV) stock closed at $184.26 per share with a market capitalization of $32.488 billion.
Hardman Johnston Global Equity Strategy stated the following regarding IQVIA Holdings Inc. (NYSE:IQV) in its Q4 2024 investor letter:
“The top sector detractors from relative performance during the quarter were Health Care and Consumer Discretionary. Within Health Care, the top detracting holdings were IQVIA Holdings Inc. (NYSE:IQV) and Elanco Animal Health, Inc. IQVIA is a contract research organization (CRO) serving biopharma industry. The company lowered its 2024 guidance due to disruptions on the clinical side of the business, with one large cancellation and two trial starts pushed into 2025. Short-term disruptions in this segment should get resolved during the first half of 2025. However, the Technology and Analytical Solutions side of the business had a positive quarter, returning to growth, with outlook for continued growth in 2025.”
A researcher in a lab with a microscope examining a sample.
IQVIA Holdings Inc. (NYSE:IQV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held IQVIA Holdings Inc. (NYSE:IQV) at the end of the fourth quarter which was 63 in the previous quarter. In the fourth quarter, IQVIA Holdings Inc. (NYSE:IQV) reported $3,958 million in revenues, up 2.3% on a reported basis and 3% constant currency. While we acknowledge the potential of IQVIA Holdings Inc. (NYSE:IQV) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we discussed IQVIA Holdings Inc. (NYSE:IQV) and shared the list of best fintech stocks to buy according to Billionaires. IQVIA Holdings Inc. (NYSE:IQV) was the Oakmark Select Fund’s top detractor in Q4 2024. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
